Semaglutide Reduced Risk for Major Kidney Disease Events by 24% for Patients with Type 2 Diabetes and Kidney Disease
American Diabetes Association Symposium Showcases New Potential Solution for Patients at High-Risk of Kidney Outcomes
Kidney disease impacts an estimated 37 million Americans including nearly 15% of the adult population. Diabetes is a major risk factor for kidney disease, and approximately one in three American adults with diabetes have chronic kidney disease. The trial aimed to evaluate if semaglutide, a once-weekly GLP-1 receptor agonist, would mitigate kidney outcomes and death.
The double-blind, randomized, placebo-controlled international trial enrolled 3,533 participants with a median follow-up period of 3.4 years. The trial compared injectable semaglutide (1.0 mg) once weekly with a placebo as an adjunct to the standard of care for the prevention of major kidney outcomes, specifically kidney failure, substantial loss of kidney function, and death from kidney or cardiovascular causes.
Participants who received semaglutide experienced a 24% risk reduction of the composite primary endpoint, including kidney outcomes and death due to cardiovascular and kidney causes, compared to those who received a placebo. In addition, the secondary endpoints showed significant improvements with semaglutide, including a slower estimated glomerular filtration rate (eGFR), a test that measures your level of kidney function and determines your stage of kidney disease, slope of 1.16 ml/min/1.73m2/year, a reduction of major cardiovascular events by 18%, and a reduction of the risk of all-cause death by 20%.
"This is a patient population at high-risk of severe kidney outcomes. Despite existing treatment options, there is still a clear unmet need for this group," said
The authors of this study note new research will follow in 2024 and 2025, looking into clinically relevant areas to address the unmet needs of this patient population.
Research presentation details:
- Symposium:
The First Dedicated Kidney Outcome Trial with a GLP-1 Receptor Agonist—Once-Weekly Semaglutide and the FLOW Trial Results - Presented on
Monday, June 24, 2024 at1:30 PM EDT
About the ADA's Scientific Sessions
The ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 83 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 136 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life®. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).
Media contact:
Amy Robinson
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/semaglutide-reduced-risk-for-major-kidney-disease-events-by-24-for-patients-with-type-2-diabetes-and-kidney-disease-302178787.html
SOURCE American Diabetes Association
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- News Xplained | Can the latest mega bridge in South China live up to expectations?
- Swiftcrypt Exchange Launches New Decentralized Trading Platform
- Swiftcrypt Exchange Launches Two-Factor Authentication System to Enhance Account Security
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!